These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34953056)

  • 1. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis.
    Tezuka S; Ueno M; Oishi R; Nagashima S; Sano Y; Kawano K; Tanaka S; Fukushima T; Asama H; Konno N; Kobayashi S; Morimoto M; Maeda S
    Cancer Med; 2022 Feb; 11(4):1088-1098. PubMed ID: 34953056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study.
    Tezuka S; Ueno M; Kobayashi S; Hamaguchi T; Yamachika Y; Oishi R; Nagashima S; Fukushima T; Morimoto M; Shin M
    Pancreatology; 2022 Sep; 22(6):789-796. PubMed ID: 35705458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
    Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
    Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
    Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
    Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study.
    Ye LF; Ren C; Bai L; Liang JY; Hu MT; Yang H; Wang ZQ; Wang FH; Xu RH; Li YH; Wang DS
    Invest New Drugs; 2021 Jun; 39(3):836-845. PubMed ID: 33411209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Yoon H; Shin Y; Ryoo BY; Jeong H; Park I; Seo DW; Lee SS; Park DH; Song TJ; Oh D; Hwang DW; Lee JH; Song KB; Park Y; Kwak BJ; Hong SM; Park JH; Kim SC; Kim KP; Yoo C
    Pancreatology; 2024 May; 24(3):424-430. PubMed ID: 38395676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
    Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
    Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
    Mizrahi JD; Rogers JE; Hess KR; Wolff RA; Varadhachary GR; Javle MM; Shroff RT; Ho L; Fogelman DR; Raghav KPS; Overman MJ; Pant S
    Pancreatology; 2020 Apr; 20(3):501-504. PubMed ID: 31932214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer.
    Satake T; Morizane C; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Ueno H; Okusaka T
    Int J Clin Oncol; 2022 Aug; 27(8):1331-1339. PubMed ID: 35637361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
    Ozaka M; Nakachi K; Kobayashi S; Ohba A; Imaoka H; Terashima T; Ishii H; Mizusawa J; Katayama H; Kataoka T; Okusaka T; Ikeda M; Sasahira N; Miwa H; Mizukoshi E; Okano N; Mizuno N; Yamamoto T; Komatsu Y; Todaka A; Kamata K; Furukawa M; Fujimori N; Katanuma A; Takayama Y; Tsumura H; Fukuda H; Ueno M; Furuse J;
    Eur J Cancer; 2023 Mar; 181():135-144. PubMed ID: 36652891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of SOXIRI
    Li X; Huang J; Wang F; Jiang Q; Huang L; Li S; Guo G
    Ther Adv Med Oncol; 2023; 15():17588359231186029. PubMed ID: 37435561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
    Zou L; Li X; Wu X; Cui J; Cui X; Song X; Ren T; Han X; Zhu Y; Li H; Wu W; Wang X; Gong W; Wang L; Li M; Lau WY; Liu Y
    BMC Cancer; 2021 Jul; 21(1):818. PubMed ID: 34266407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Single-Center Retrospective Study to Compare the Efficacy and Safety of Modified FOLFIRINOX with S-1 as Adjuvant Chemotherapy in 71 Patients with Resected Pancreatic Carcinoma.
    Yao L; Tang C; Feng W; Dai H
    Med Sci Monit; 2022 Jun; 28():e937136. PubMed ID: 35718990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
    Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
    Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer.
    Irisawa A; Takeno M; Watanabe K; Takahashi H; Mitsunaga S; Ikeda M
    Sci Rep; 2022 Sep; 12(1):15574. PubMed ID: 36114233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
    Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
    ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
    Ramanathan RK; McDonough SL; Philip PA; Hingorani SR; Lacy J; Kortmansky JS; Thumar J; Chiorean EG; Shields AF; Behl D; Mehan PT; Gaur R; Seery T; Guthrie KA; Hochster HS
    J Clin Oncol; 2019 May; 37(13):1062-1069. PubMed ID: 30817250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer.
    Ikezawa K; Kiyota R; Takada R; Daiku K; Maeda S; Imai T; Abe Y; Kai Y; Yamai T; Fukutake N; Nakabori T; Ashida R; Uehara H; Tabuchi T; Katayama K; Ohkawa K
    JGH Open; 2021 Jun; 5(6):679-685. PubMed ID: 34124386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.